Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Akebia Therapeutics history
Akebia Therapeutics company history timeline
Since our founding in 2007, we’ve put tenacity and innovation to work to develop unique therapeutics that have the potential to set new standards of care for people living with kidney disease.
John P. Butler joined Akebia as a director in July 2013 and was appointed as the President and Chief Executive Officer of Akebia in September 2013.
ZS Pharma, Inc. was acquired by AstraZeneca in 2015.
Doctor Gilman had served as a member of the Board of Directors of Keryx from March 2016 until completion of the Merger.
Prior to joining Duke University in 2016, Doctor Wolf held faculty, leadership and administrative positions at Harvard Medical School, the University of Miami and Northwestern University.
In August 2018, Aralez voluntarily commenced restructuring proceedings in Canadian Court and its United States-based subsidiaries, including POZEN, Inc., filed voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code.
Adrian Adams has served as a member of our Board of Directors since completion of the Merger with Keryx in December 2018.
Myles Wolf, M.D., M.M.S.C., joined as a member of our Board of Directors in April 2020.
He has served as Chief Financial Officer of Apnimed, Inc., a clinical stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, since November 2020.
Ron Frieson has served as a member of our Board of Directors since November 2021.
Rate Akebia Therapeutics' efforts to communicate its history to employees.
Akebia Therapeutics jobs
Do you work at Akebia Therapeutics?
Does Akebia Therapeutics communicate its history to new hires?
Akebia Therapeutics competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Abraxis BioScience | 2007 | $359.0M | 885 | - |
| Argos Therapeutics | 1997 | $1.9M | 76 | - |
| ImmunoGen | 1981 | $108.8M | 75 | - |
| Tetraphase Pharmaceuticals | 2006 | $7.4M | 67 | 3 |
| Karyopharm | 2008 | $145.2M | 442 | 16 |
| Turning Point Therapeutics | 2013 | $25.0M | 142 | - |
Akebia Therapeutics history FAQs
Zippia gives an in-depth look into the details of Akebia Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Akebia Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Akebia Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Akebia Therapeutics. The data presented on this page does not represent the view of Akebia Therapeutics and its employees or that of Zippia.
Akebia Therapeutics may also be known as or be related to AKEBIA THERAPEUTICS INC., Akebia Therapeutics, Akebia Therapeutics Inc, Akebia Therapeutics Inc. and Akebia Therapeutics, Inc.